Search

Aim. To study the effects of hormone replacement therapy (HRT) on metabolic profile, insulin resistance (IR), central and peripheral hemodynamics, endothelial function and antioxidant activity in postmenopausal women with metabolic syndrome (MS).Material and methods. The study included 30 postmenopausal women with MS, receiving Angeliq medication (estradiol 1 mg, drospirenone 2 mg) for 6 months. At baseline and 6 months after the start of the treatment, fasting and two-hour postprandial levels of lipids, glucose, and insulin were measured. The other parameters included HOMA-IR index, body composition and visceral fat percentage, 24-hour blood pressure monitoring (BPM), echocardiography, microcirculation (MC) parameters, endothelial dysfunction and oxidative stress markers.Results. Mean body mass index (BMI) decreased from 30,9 kg/m2 to 30,2 kg/m2 (р=0,068), while mean visceral fat percentage changed from 40,6% at baseline to 42,2% after 6 months (р=0,002). These changes were explained by natural menopause course, as well as progressing IR and menopausal MS. BP levels were effectively reduced, according to the 24-hour BPM data; all participants achieved target BP levels. Left ventricular (LV) myocardial mass index significantly decreased from 116,1 to 110,8 (р

Aim. To compare the effects of antihypertensive medications (AHM) on central hemodynamics, metabolic profile, insulin resistance (IR), oxidant and antioxidant systems in postmenopausal patients with metabolic disturbances and Stage I-II arterial hypertension (AH).Material and methods. The study included 47 postmenopausal women with metabolic syndrome (MS) and Stage I-II AH. Group I (n=31) received an ACE inhibitor spirapril (6 mg/d) for 6 months. Group II (n=16) received various AHM administered as a part of ambulatory therapy. At baseline and after 6 months of the treatment, all participants underwent 24-hour blood pressure monitoring (BPM), echocardiography, lipid profile (LP) and IR index HOMA assessment, oral glucose tolerance test, double energy X-ray absorptiometry with general and regional analysis of body composition, as well as the measurement of lipid acylhydroperoxide levels and erythrocyte superoxide dismutase activity.Results. In both groups, target BP levels were achieved. In Group I, left ventricular myocardial mass index (LVMMI) significantly decreased (р

Aim. То compare the effects of hormone replacement therapy (HRT) and antihypertensive therapy (AHT) on metabolic profile, insulin resistance (IR) and central hemodynamics in postmenopausal women with metabolic syndrome (MS).Material and methods. In total, 46 postmenopausal women with MS were examined. Group I (n=30) received estradiol (1 mg/day) and drospirenone (2 mg/day) for 6 months (Angeliq medication). Group II (n=16) received various antihypertensive medications. At baseline and after 6 months of the treatment, lipid profile, glycemia and insulinemia, IR index HOMA-IR, body composition, Kuperman index (modified by E..M. Vikhlyaeva) were assessed, 24-hour blood pressure monitoring (BPM) and echocardiography were performed.Results. In Group I, body mass index (BMI) reduced from 30,9 kg/m2 to 30,2 kg/m2 (p=0,068); in Group II, it increased from 30,6 kg/m2to 31,3 kg/m2 (p=0,003). Visceral fat tissue percentage was 40,6 %. at baseline and 42,2 % after 6 months in Group I, comparing to 41,0 % and 42,2 %, respectively, in Group II (p=0,018). Angeliq medication demonstrated good antihypertensive activity. In Group I, left ventricular myocardial mass index (LVMMI) significantly reduced from 116,1 g/m2 to 110,8 g/m2 (p